Skip to main content
Premium Trial:

Request an Annual Quote

Study Validates Analytical, Clinical Performance of Automated BG Medicine Galectin-3 Test

Premium

BG Medicine noted this week the publication of a study validating the analytical and clinical performance of an automated version of its BGM Galectin-3 heart failure test.

Published in Clinica Chimica Acta, the study used BioMérieux's VIDAS Galectin-3 assay, which the company has developed in partnership with BG, to analyze blood samples from 137 patients with chronic heart failure.

The study found that elevated galectin-3 levels as measured by the assay were predictive of fatal cardiovascular events and the severity of heart failure among these patients. It also found that the analytical performance of the automated assay matched that of the conventional, manual BGM Galectin-3 test.

In a statement, BG Medicine President and CEO Paul Sohmer said the results "support commercialization of the VIDAS Galectin-3 assay in Europe and substantiate our efforts to assist BioMérieux with its pursuit of [US Food and Drug Administration] 510(k) clearance of the assay in the US."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.